Pituitary adenylate cyclase-activating polypeptide (PACAP) is a pleiotropic peptide with autocrine neuroprotective and paracrine anti-inflammatory properties in various models of acute neuronal damage and neurodegenerative diseases. Therefore, we examined a possible beneficial role of endogenous PACAP in the superoxide dismutase 1, SOD1(G93A), mouse model of amyotrophic lateral sclerosis (ALS), a lethal neurodegenerative disease particularly affecting somatomotor neurons. In wild-type mice, somatomotor and visceromotor neurons in brain stem and spinal cord were found to express the PACAP specific receptor PAC1, but only visceromotor neurons expressed PACAP as a potential autocrine source of regulation of these receptors. In SOD1(G93A) mice, only a small subset of the surviving somatomotor neurons showed induction of PACAP mRNA, and somatomotor neuron degeneration was unchanged in PACAP-deficient SOD1(G93A) mice. Pre-ganglionic sympathetic visceromotor neurons were found to be resistant in SOD1(G93A) mice, while pre-ganglionic parasympathetic neurons degenerated during ALS disease progression in this mouse model. PACAP-deficient SOD1(G93A) mice showed even greater preganglionic parasympathetic neuron loss compared to SOD1(G93A) mice, and additional degeneration of preganglionic sympathetic neurons. Thus, constitutive expression of PACAP and PAC1 may confer neuroprotection to central visceromotor neurons in SOD1(G93A) mice via autocrine pathways. Regarding the progression of neuroinflammation, the switch from amoeboid to hypertrophic microglial phenotype observed in SOD1(G93A) mice was absent in PACAP-deficient SOD1(G93A) mice. Thus, endogenous PACAP may promote microglial cytodestructive functions thought to drive ALS disease progression. This hypothesis was consistent with prolongation of life expectancy and preserved tongue motor function in PACAP-deficient SOD1(G93A) mice, compared to SOD1(G93A) mice. Given the protective role of PACAP expression in visceromotor neurons and the opposing effect on microglial function in SOD1(G93A) mice, both PACAP agonism and antagonism may be promising therapeutic tools for ALS treatment, if stage of disease progression and targeting the specific auto-and paracrine signaling pathways are carefully considered.
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Introduction
Pituitary adenylate cyclase-activating polypeptide (PACAP), initially isolated from the hypothalamus (Miyata et al., 1989) , is a member of the vasoactive intestinal polypeptide (VIP)/secretin/glucagon superfamily. Two biologically active PACAP isoforms of different length exist, PACAP-38 and the C-terminally truncated PACAP-27 (Miyata et al., 1989 , 1990 , with PACAP-38 being the predominant form (Arimura et al., 1991) . PACAP is found in numerous areas and neuron types throughout the central and peripheral nervous system, e.g. in hippocampus, amygdala, substantia nigra, cerebellar granule cells and sensory neurons in the dorsal root ganglia, as well as sympathetic, parasympathetic and some somatomotor neurons (reviewed by Hannibal, 2002; Fahrenkrug and Hannibal, 2004) . PACAP acts in an autocrine and paracrine manner through activation of three G-protein-coupled transmembrane receptors. PAC1 is the PACAPspecific receptor predominantly expressed in brain and adrenal chromaffin cells. VPAC1 and VPAC2 bind PACAP and the related neuropeptide VIP with similar affinities and are expressed by various cell types including neurons, glia cells, endothelial cells, lymphocytes and 
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